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Caspase-8 belongs to the cysteine protease family and is known to be activated at the initial step in the cascade of TRAIL-induced
apoptosis. The activation of procaspase-8 can be blocked by a relatively large amount of c-FLIP, which renders resistance to death receptor-
mediated apoptosis in many types of cancer cells. To ask if extrinsic over-expression of caspase-8 contributes to the induction of apoptosis, we
introduced the caspase-8 gene into HCC cells using an adenoviral (Adv) vector (Adv-Casp8). We demonstrated that Adv-Casp8 increased
expression of active forms of caspase-8 in MOI-dependent manner. A large amount of Adv-Casp8 (MOI of 50) induced apoptosis significantly
in HCC cells and resulted in downregulation of c-FLIP (in SK-Hep1, HLE, and HepG2 cells), XIAP, survivin, and Bcl-xL (in HLE cells) and
dynamic release of cytochrome c and Smac from the mitochondria into the cytosol. On the other hand, a small amount of Adv-Casp8 (MOI of
10) causes a slight but detectable increase in the level of apoptosis with only a small effect on anti-apoptotic proteins and mitochondrial
activation. However, small amounts of Adv-Casp8 augmented TRAIL- or chemotherapeutic agent-induced cell death (with an MOI of 10 or
20, respectively). These results suggest both that exogenous over-expression of caspase-8 by Adv-Casp8 may be essential for induction of
HCC cell death and that the combination of Adv-Casp8 and TRAIL or chemotherapeutic agents could provide a useful strategy for treatment
of HCC.
© 2006 Elsevier B.V. All rights reserved.1. Introduction
The process of programmed cell death, apoptosis, is fun-
damental in developmental and homeostatic maintenance of
complex biological systems [1–4]. Mis-regulation or failure of
normal apoptotic mechanisms can contribute to transformation
of cells and provide a growth advantage to cancer cells [5].Abbreviations: TRAIL, TNF-related apoptosis-induced ligand; TRAIL-R1,
TRAIL-receptor 1; TRAIL-R2, TRAIL-receptor 2; DISC, death-inducing
signaling complex; HCC, hepatocellular carcinoma; XIAP, X-linked inhibitor
of apoptosis proteins; c-FLIP, cellular FLICE/caspase-8-inhibitory protein; NF-
κB, nuclear factor-κB; AxCALNL-hCaspase-8, Adv-Casp8, Recombinant
adenovirus expressing human caspase-8; AxCANCre, Adv-Cre, Recombinant
adenovirus expressing Cre recombinase; MOI, multiplicity of infection; CPT,
camptothecin; DOX, doxorubicin; CDDP, Cisplatin; 5-FU, 5-Fluorouracil; COX
IV, Cytochrome oxidase subunit IV; IAPs, the inhibitor of apoptotic proteins;
Smac, second mitochondrial-derived activator of caspase; DIABLO, the direct
IAP binding protein with low pI
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doi:10.1016/j.bbamcr.2006.03.012Apoptosis can be triggered by the engagement of any one of
several cell surface death receptors, each of which expresses
extracellular cysteine-rich pseudo-repeats and contains homol-
ogous intracellular carboxyl-terminal death domains. Moreover,
these cell surface receptors are members of the TNF-receptor
(TNF-R) family and include Fas, TNF-receptor 1(TNF-R1);
TNF-related apoptosis-induced ligand (TRAIL)-receptor 1(R1),
TRAIL-R2, and TRAMP [4,6,7]. Stimulation of Fas, TRAIL-
R1, or TRAIL -R2 results in clustering of the receptor, which in
turn leads to recruitment of an adaptor molecule and the Fas-
associated death domain (FADD) protein. Recruitment of these
factors causes the receptor proximal to caspase-8 to become
activated upon recruitment to the death-inducing signaling com-
plex (DISC) via homophilic DED-DED interactions. Caspase-
8 belongs to the cysteine protease family of proteins, whose
members are activators of executioner caspases, and is activated
at the initial step in the cascade of Fas- or TRAIL-induced
apoptosis [6,8]. Activated caspase-8 then initiates the apoptosis
executing caspase cascade [9].
Fig. 1. Adv-mediated induction of caspase-8 in HCC cells. (A) Dose-dependent
expression of caspase-8 by Western blot analysis in human HCC cell lines SK-
Hep1 24 h after infection with Adv-Casp8 or Adv-Cre (control) at the indicate
MOI. Co-infection ratio of Adv-Casp8 and Adv-Cre was 2:1. (B) Expression of
caspase-8 in three cell lines, SK-Hep1, HLE, and HepG2. Cells were infected
with Adv-Casp8 and Adv-Cre at MOI 10/5. For control experiments, cells were
incubated with Adv-Cre alone at the same total MOI. Lysates were harvested at
48 h post-infection. Jurkat cell lysates were used as a positive control. (C) Effects
of Adv-Casp8 expression on HCC cell viability. (SK-Hep1; closed columns,
HLE; gray columns, and HepG2; open columns). Cells were infected with Adv-
Casp8 or Adv-Cre (control) at the indicated MOIs for 48 h. Cell viability was
assessed by MTT. The data are reported as a percent viability versus the control
and represent the means±S.D. of six independent experiments.
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sistance to stimuli that induce apoptosis. Since this apoptotic
sensitivity is closely related to resistance to conventional antican-
cer agents and radiotherapy, providing cells with a way to over-
come apoptosis resistance may be critical for establishment of
effective new strategies for treatment of HCC. Several cellular
anti-apoptotic mechanisms exist in cells, including reduced ex-
pression of Fas [10,11] or caspases [12]; expression of anti-apop-
totic proteins, Bcl-2 family proteins [13,14], and proteins in the
various inhibitor of apoptosis families, such as survivin and X-
linked inhibitor of apoptosis proteins (XIAP) [15,16]; or receptor-
mediated survival signals [17,18]. Thesemechanisms contribute to
resistance against immunologic cytotoxicity in human HCC cells.
Among caspase inhibitors, it may be cellular FLICE/caspase-
8-inhibitory protein (c-FLIP) that is crucial for modulation of the
cell death signal by inhibition of procaspase-8 processing at
DISC. A recent study demonstrated that small amounts of c-FLIP
allow for processing of procaspase-8, leading to the formation of
the active caspase-8 heterotetramer, which is composed of the p18
and p10 subunits, but that the presence of large amounts of c-FLIP
blocks cleavage of procaspase-8 [19]. In a previous study, we
have demonstrated that c-FLIP is over-expressed in human HCC
tissues and HCC cell lines and plays an important role in cell
survival not simply by inhibiting death receptor-mediated
apoptosis but also by regulating NF-κB activation [20].
Taken together, the results suggest that DISC formation by
caspase-8 and c-FLIP is a critically important anti-apoptotic
mechanism and thus, that is an ideal therapeutic gene target. In
support of this idea, a recent study revealed that the relative
levels of caspase-8 and c-FLIP are an important determinant of
susceptibility to Fas-mediated apoptosis in malignant cells
[19,21]. Although it is not clear what level or levels of c-FLIP
function can increase apoptosis sensitivity, we tested transfer of
the caspase-8 gene into HCC cells using adenovirus vector in an
attempt to alter the c-FLIP, caspase 8 ratio and ask if apoptosis is
affected. To do this, the expression level of caspase-8 must be
lower than levels that results in self-oligomerization of caspase-
8 precursor proteins in order to prevent a high level of non-
specific apoptosis in non-transformed cells.
Previous studies demonstrated that TRAIL and chemother-
apeutic drugs-induced cytotoxicity is closely related with apop-
totic pathway. However, there is little report concerning the
increased sensitivity of TRAIL and a panel of chemotherapeutic
agent using caspase overexpression. Therefore, to explore the
possibility that caspase-8 gene transfer could be useful in a gene
therapy approach to the treatment of HCC cells, we asked if
adv-mediated caspase-8 gene transfer could selectively affect
cell growth and survival and augment TRAIL- or chemother-
apeutic agent-induced apoptosis in HCC cells.
2. Materials and methods
2.1. Cell culture
The human HCC cell lines SK-Hep1 and HepG2 were purchased from the
American Type Culture Collection (Rockville, MD). The HLE cell line (JCRB
0404) was purchased from the Health Science Research Resource Bank (Osaka,
Japan). All HCC cells were cultured in Dulbecco's modified Eagle medium(Dainippon Pharmaceutical Co. Ltd., Osaka, Japan) supplemented with 1%
penicillin/streptomycin (GIBCO BRL, Grand Island, NY) and 10% heat-
inactivated fetal calf serum (GIBCO BRL) in 5% CO2 at 37 °C.
2.2. Recombinant adenoviral vectors
Recombinant adenovirus expressing human caspase-8 (AxCALNL-hCas-
pase-8, referred to here as Adv-Casp8) was kindly provided by Dr. Hirofumi
Hamada (Sapporo Medical University, Hokkaido, Japan). This recombinant
adenovirus vector utilized the Cre/loxP system [22] in order to prevent damage to
293 virus producer cells induced by pro-apoptotic gene products such as caspase-
8. In the vector, the human caspase-8 precursor can be expressed via the CA
promoter but is silenced by a polyadenylate sequence flanked by a pair of loxP
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promoter becomes juxtaposed to the caspase-8 gene, resulting in constitutive
activation of the gene. Recombinant adenovirus expressing Cre recombinase
(AxCANCre, referred to here as Adv-Cre) was purchased from Takara Shuzo
Co., LTD. (Shiga, Japan). The viruses were propagated and purified, and viral
titers were determined in 293 cells with the Adeno-X Rapid Titer Kit (BD
Biosciences Clontech). Purified recombinant virus were kept at −80 °C until use.
Cells were seeded on the appropriate plates or dishes at a concentration of
2×105/ml 1 day prior to infection. Before infection, the culture medium was
discarded and cells were washed in culture medium without antibiotics or fetal
calf serum. For infection, the diluted viral solution was added to the target cells
and after incubation for 1 h at 37 °C, growth medium was added and cells were
cultured for 48 h. Adv-mediated caspase-8 gene transfection was performed by
co-infection of Adv-Casp8 and Adv-Cre at a MOI of 2:1. In control experiments,
cells were incubated with Adv-Cre alone at the same total MOI.
2.3. Assessment of viability of HCC cells
The HCC cells were plated at a density of 1×104 cell/well in 96-well
microtiter plates (Corning Glass Works, Corning, NY) and each plate was
incubated for 24 h, followed by addition of the diluted viral solution. After 24 h,
the plates were incubated for 24 h with various concentrations of the following:
recombinant human TRAIL (R&D Systems, Inc., Minneapolis, MN); (S)-(+)-
camptothecin (camptothecin, Sigma); doxorubicin hydrochloride (doxorubicin,
Sigma); cis diamminedichloroplatinum (Cisplatin, Sigma); Paclitaxel (Taxol,
Sigma); or 5-Fluorouracil (5-FU; Sigma). The live-cell count was assayed by the
3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) assay
using a Cell Titer 96 assay kit (Promega, Madison, WI) according to the
manufacturer's instructions. The absorbance of each well was measured at 570/
633 nm with a microtiter plate reader (Bio-Rad Laboratories, Hercules, CA).Fig. 2. Adv-Casp8-induced apoptosis in HLE cells. Cells were infected by either (A)
Cre at MOI of 15 (control for A), or (D) Adv-Cre at MOI of 75 (control for B) for 48
and demonstrated the representative figure (×200). Note the typical apoptotic featur2.4. Immunoblotting and antibodies
Expression of caspase-8, caspase-3, FLIP, XIAP, survivin, Bcl-xL, Smac,
and cytochrome c was analyzed by immunoblotting. Cells were harvested an
appropriate number of hours after transfection and lysed on ice in lysis buffer
(50 mmol/L Tris–HCl pH 8, 150 mmol/L NaCl, 5 mmol/L ethylenediaminete-
traacetic acid, 1% NP-40, 1 mmol/L phenylmethylsulfonyl fluoride). Total
protein levels were measured using a Bio-Rad Protein Assay Kit (Bio-Rad
Laboratories, Hercules, CA). Equal amounts of protein from each extract were
separated by 12.5% sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and transferred onto PVDF membranes (Millipore Corporation,
MA). Blots were blocked by incubation in 5% milk with Tris–HCl (pH 7.5) and
0.1% Tween 20 for 2 h at room temperature and probed overnight at 4 °C with
primary antibodies. The following primary antibodies were used: mouse anti-
human caspase-8 monoclonal (Cell Signaling Technology, Beverly, MA), mouse
anti-caspase-3/CPP32 monoclonal, mouse anti-hILP/XIAP monoclonal, rabbit
anti-Bcl-xL polyclonal (Transduction Laboratories, Lexington, KY), rabbit anti-
c-FLIP polyclonal (Medical and Biological Laboratories Co., LDT, Nagoya,
Japan), mouse anti-survivin monoclonal, goat anti-Smac polyclonal (Santa Cruz
Biotechnology, Inc. Santa Cruz, CA), rabbit anti-cytochrome c polyclonal
(CLONTCH Laboratories, Inc., CA), mouse anti-COX IV monoclonal (Abcam
Ltd., Cambridge,UK), andmouse anti-α-Tubulinmonoclonal (OncogeneResearch
Products, San Diego, CA). Antibodies were diluted with 5% milk in Tris–HCl
(pH 7.5) and 0.1% Tween 20. The immunoblots were then probed with hor-
seradish peroxidase-conjugated anti-mouse immunoglobulin G (IgG), horserad-
ish peroxidase-conjugated anti-rabbit IgG (diluted 1:1000 with 1%milk in Tris–
HCl pH 7.5) (Amersham Biosciences, Buckinghamshire, UK) or horseradish
peroxidase-conjugated anti-goat IgG. (1:2000 dilution) (Zymed Laboratories,
South San Francisco, CA). After the final wash, the signal was detected with an
ECL kit (Amersham Pharmacia Biotech, Buckinghamshire, UK).Adv-Casp8/Cre at MOI of 10/5, (B) Adv-Casp8/Cre at MOI of 50/25, (C) Adv-
h. Cell nuclei were visualized with DAPI. We observed five fields, respectively,
es, nuclear condensation and nuclear fragmentation.
847Y. Yamaguchi et al. / Biochimica et Biophysica Acta 1763 (2006) 844–8532.5. Cellular fractionation
Two 10 cm culture dishes per sample were collected and washed twice in
ice-cold Wash Buffer (CLONTECH Laboratories, Inc.). Whole-cell pellets were
resuspended in ice-cold Fractionation Buffer Mix (0.2% Protease Inhibitor
Cocktail, 0.1% DTT and Fractionation Buffer; CLONTECH Laboratories, Inc.)
and subjected to 40 strokes in an ice cold Dounce tissue grinder. The homo-
genates were subjected to centrifugation at 700×g for 10 min at 4 °C. The
supernatant was subsequently subjected to centrifugation at 10,000×g for 25 min
at 4 °C to obtain a cytosolic fraction (supernatant) and a mitochondrial fraction
(pellet).The pellets were suspended in Fractionation Buffer Mix. Cytochrome
oxidase subunit IV (COX IV) and α-Tubulin were used as controls for the
mitochondrial and cytosolic fractionations, respectively.
2.6. Detection of apoptosis
A total of 1×105 HLE cells were cultured in 35 mm culture dishes for 24 h,
followedby addition of the diluted viral solution.After incubation for 48 h, cell nuclei
were stained with 4’6,-diamidino-2-phenylindole (DAPI; Sigma, St. Louis, MO,
USA) and observed under a fluorescence microscope (Zeiss, Göttingen, Germany).Fig. 3. Effect of Adv-Casp8 on TRAIL-induced apoptosis in HCC cell lines.
HCC cells, (A) SK-Hep1, (B) HLE, and (C) HepG2, were infected by either
Adv-Casp8/Cre at MOI of 10/5 (■), or Adv-Cre at MOI of 15 as control (□) for
24 h. And they were incubated with various concentrations of TRAIL for 24 h.
Cell viability was assessed by MTT. The data are shown as the percent viability
as compared to cells without TRAIL treatment, respectively, and represent the
mean±S.D. of six independent experiments.3. Results
3.1. Adv-mediated caspase-8 increased expression of
procaspase-8 and cleaved caspase-8 in HCC cells
We first determined the expression levels of caspase-8 from
the adenovirus vector in SK-Hep1 cells. Infection of SK-Hep1
cells with AxCALNL-hCaspase-8 (Adv-Casp8) and AxCACre
(Adv-Cre) at MOIs ranging from 10 to 100 for 24 h induced
increased intracellular expression levels of procaspase-8 and
cleaved caspase-8 in a MOI-dependent manner, whereas Adv-
Casp8 or Adv-Cre alone could not (Fig. 1A). These results
agreed with the report that over-expression of procaspase-
8 leads to self-activation of caspase-8 [23]. We next investigated
expression of caspase-8 in three HCC cell lines (SK-Hep1,
HLE, and HepG2) 48 h after infection with the adenovirus
vectors. An increase in the caspase-8 expression level was
visible at MOI of 10 in three HCC cell lines (Fig. 1B).
3.2. Adv-Casp8 induced apoptosis in HCC cells
The effect of Adv-Casp8 expression on the viability of HCC
cells was then assessed by the MTT assay. Infection of HCC
cells with Adv-Casp8 at MOI of 10 did not markedly affect cell
viability 48 h after infection. However, viability of cells infected
with Adv-Casp8 did decrease in a MOI-dependent manner (Fig.
1C). Since we wished to explore whether a sublethal dose of
Adv-Casp8 could augment apoptosis elicited by TRAIL or
chemotherapeutic agents, we chose the sub-lethal dose of MOI
of 10 or 20 for subsequent experiments.
In order to determine if Adv-Casp8 induces apoptosis in
HCC cells, we assessed DAPI staining 48 h after infection of
either Adv-Casp8 and Adv-Cre or Adv-Cre alone (at the same
total MOI) in HLE cells. Apoptosis was not induced in cells
infected with Adv-Cre alone. As expected, however, Adv-
Casp8-infected cells did show typical apoptotic features,
including nuclear condensation and nuclear fragmentation
with DAPI staining (Fig. 2).3.3. Adv-Casp8 augmented TRAIL- induced cell death
It is well known that HCC cell lines showed resistance to
TRAIL-induced apoptosis caused by nuclear factor-κB (NF-κB)
activation induction of genes whose products provide resistance
to apoptosis. In order to assess the effects of Adv-Casp8 on
TRAIL induced cell death, 24 h after of infection cells were
incubated with TRAIL at various concentrations for 24 h and cell
viability was assessed by the MTT assay (Fig. 3). Viability of
Adv-Casp8 infected cells treated with TRAIL decreased
synergistically or additively and in a dose-dependent manner;
the effect was observed for all cell lines.
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cell death
In recent studies, it was shown that suppression of inhibitor of
apoptosis proteins such as XIAP or survivin augmented
chemotherapeutic agent-induced cell death on HCC cell lines
[24]. To examine the effect of Adv-Casp8 on chemotherapeutic
agent-induced cell death in HCC cell lines, 24 h after of infection
of adenovirus vectors, infected cells were incubated with
Cisplatin, Taxol, camptothecin, doxorubicin, or 5-FU for 24 h
and cell viability was assessed using the MTTassay (Fig. 4A, B,
C). The doses of the chemotherapeutic agents were determined
by calculating the 50% growth suppression value (IC50) in
preliminary experiments (data not shown). At MOI of 20, Adv-
Casp8 resulted in a decrease in cell viability in all cell lines when
combined with chemotherapeutic agents, whereas at MOI of 10,
Adv-Casp8 resulted in a decrease in cell viability only in the
HLE cell line. In addition, we assessed DAPI staining with HLE
cells, which were incubated with Cisplatin, Taxol, or 5-FU for
24 h after infection of adenovirus vectors (Fig. 4D). In infected
cells with Adv-Casp8 at MOI of 20, we detected many apoptoticFig. 4. Effect of Adv-Casp8 on Chemotherapeutic agent- induced cell death in HCC
either Adv-Casp8/Cre at MOI of 10/5 (gray columns), Adv-Casp8/Cre at MOI of 20/
Cre at MOI of 30 as control (dot columns) for 24 h. And they were incubated with che
Taxol 50 nM, camptothecin 0.7 μg/ml, doxorubicin 0.5 μg/ml, and 5-FU 500 μM, (
1.0 μg/ml, and 5-FU 80 μM. Cell viability was assessed by MTT. The data shown are
Means±S.D. of six independent experiments are shown. (D) HLE cells with DAPI
MOI of 30 (control) and moreover incubation with Cisplatin 100 μM, Taxol 100 μMcells. And these apoptotic cell numbers were almost in
proportion to the cell death ratio estimated by MTT assay.
3.5. Adv-Casp8 decreased expression level of c-FLIP and other
Anti-apoptotic proteins
As shown by recent studies, over-expression of caspase-8 by
Adv-Casp8 suppressed expression of FLIP but increased
expression of FADD and caspase-3 activity in human gastric
adenocarcinoma cells [25]. To investigate whether caspase-
8 over-expressed using the transgenic construct Adv-Casp8
could alter the expression levels of anti-apoptotic proteins or
activity of caspase-3 in HCC cells, immunoblot analyses of c-
FLIP, XIAP, survivin, Bcl-xL, and procaspase-3 were
performed. Expression of survivin and procaspase-3 decreased
in two cells, c-FLIP was suppressed in SK-Hep1 cells, and
XIAP was suppressed in HLE cells by Adv-Casp8 at MOI of
10. Moreover, expression of c-FLIP and procaspase-3
decreased in all cell lines at MOI of 50 and XIAP, survivin,
Bcl-xL were suppressed by Adv-Casp8 at MOI of 50 in HLE
cells (Fig. 5).cell lines. HCC cells, (A) SK-Hep1, (B) HLE, and (C) HepG2, were infected by
10 (closed columns), Adv-Cre at MOI of 15 as control (open columns), or Adv-
motherapeutic agents for 24 h at the IC50 concentration for (A) Cisplatin 500 μM,
B) (C) Cisplatin 100 μM, Taxol 100 μM, camptothecin 0.5 μg/ml, doxorubicin
the absorbance at 570 nm, which is directly proportional to the number of cells.
staining after infection of either Adv-Casp8/Cre at MOI of 20/10 or Adv-Cre at
, or 5-FU 80 μM for 24 h (×200).
Fig. 5. Change in expression of anti-apoptotic proteins and procaspase-3 by Adv-Casp8 infection in HCC cell lines. Cells were harvested 48 h after infection, and cell lysates
were separated bySDS-PAGEand transferred onto PVDFmembranes. Protein levelswere then detected by immunoblotting using antisera that recognize the indicated proteins.
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Mitochondrial release of Smac/DIABLO and cytochrome c
into the cytosol has an important role in apoptosis, including
TRAIL -induced apoptosis of malignant cells [26,27]. We next
asked if over-expression of caspase-8 in HCC cells via Adv-
Casp8 promotes release of Smac and cytochrome c from
mitochondria. To do this, we used immunoblotting to detect the
levels of Smac and cytochrome c in mitochondrial and cytosolic
fractions from Adv-Casp8-infected cells.
In cells infected by Adv-Casp8 at MOI of 50, the levels of
mitochondrial Smac and cytochrome c were lower than those in
control cells and the cytosolic levels of both proteins were
higher than those in control(Fig. 6B, C), while definite effect
was determined in infected cells by Adv-Casp8 at MOI 10 (Fig.
6A, C). Over-expression of caspase-8 via Adv-Casp8 promoted
release of Smac and cytochrome c from mitochondria to cy-
tosol; thus, the mitochondrial pathway of apoptosis was acti-
vated by Adv-Casp8.
4. Discussion
The c-FLIP protein can modulate activation of procaspase-
8 and thereby prevent induction of apoptosis mediated by death
receptors. In this way, many cancer cell types are rendered
resistant to death receptor-mediated apoptosis. Moreover, c-
FLIP exerts other physiological functions related to cell pro-
liferation and tumorigenesis. Therefore, c-FLIP is thought to be a
critical target for therapeutic intervention [28]. We have
demonstrated that there is a high level of expression of c-FLIP
in human HCC tissues and cells. Conversely, c-FLIP is
downregulated by chemotherapeutic agents [20] that normally
act to augment TRAIL-induced apoptosis [29]. A large ratio of c-
FLIP to procaspase-8 blocks cleavage of procaspase-8 [19].
Recent studies demonstrated that deletion or mutation of thecaspase-8 gene is present in some cancer cells, including HCC,
which presumably results in loss of the caspase-8 apoptotic
function and contributes to pathogenesis [30–33]. These data
suggest the importance of caspase-8 in hepatocarcinogenesis
and that caspase-8 may be effective target for gene therapy.
Indeed, efficient upregulation of procaspase-8 by adenovirus-
mediated transfer of caspase-8 can induce apoptosis in several
transformed cells [25,34–36].
In this study, we demonstrated that adenovirus-mediated
transfer of the caspase-8 gene induces a significant level of
apoptosis in an MOI-dependent manner. These results were in
accordance with a report that showed that over-expression of
procaspase-8 leads to self-activation of caspase-8 and subse-
quent induction of apoptosis [23]. Adenoviral vectors are
considered a useful tool in cancer gene therapy since they can be
used to efficiently introduce genes into many types of cancer
cells. Recently, it was shown that Adv-Casp8-mediated gene
transfer efficiently induced apoptosis in glioma cells [34].
However, over-expression of caspase-8 may induce apoptosis in
all Adv-Casp8-infected cells rather than selective inhibition of
detached cells. It is, therefore, necessary to reduce nonspecific
cell death from over-expression of caspase-8 for anticancer
therapy. For this purpose, the level of caspase-8 expression from
the adenovirus vector must be lower than that which results in
self-oligomerization of caspase-8 precursor proteins [25]. Thus,
we considered that only relatively low levels of caspase-
8 would be useful to augment cell death in HCC cells and
accordingly, we used Adv-Casp8 at MOI of 10 or 20 to sensitize
cytokine or chemotherapeutic agents in our study.
TRAIL, a member of the TNF family, selectively induces
apoptosis in a variety of transformed cell lines. Interestingly,
several tumor cell lines and most normal cells are, by contrast,
resistant to TRAIL-mediated apoptosis [37]. This selective
toxicity is the basis for the current enthusiasm for TRAIL as a
potential target of novel anticancer therapeutics [38]. Previous
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mediated apoptosis, despite the fact that they express TRAIL
receptors. In the current study, whereas Adv-Casp8 infection at
MOI of 10 inducedminimal cell death inHCC cells, it augmented
TRAIL-induced apoptosis synergistically in HCC cells.
Recently, we demonstrated that high levels of TRAIL-R1/
DR4 and -R2/DR5 are expressed in human HCC tissues but that
HCC cells are resistant to TRAIL-induced apoptosis. There are
several molecular mechanisms that may account for this
resistance. The first to consider is that c-FLIP is expressed at
high levels in HCCs. C-FLIP blocks the cleavage of
procaspase-8 at DISC and activates NF-κB pathways involved
in cell proliferation or differentiation. In fact, TRAIL also
activates NF-κB, which controls expression of genes whose
products provide resistance to apoptosis, including c-FLIP, theFig. 6. Mitochondrial changes 48 h after infection of Adv-Casp8. After infection of (
(C) fractions were prepared and subjected to immunoblot analysis to detect Smac and
mitochondrial and cytosolic fractions, respectively. Protein signals were quantified by
bands. (C) The relative ratios of Adv-Casp-8 to control are shown. (MOI of 10; opeinhibitor of apoptotic proteins (IAPs), Bcl-2, and Bcl-xL
[39,40]. The IAPs regulate apoptosis by preventing the action
of the central execution phase of apoptosis through direct
inhibition of the effector caspase-3 and/or caspase-7 [41,42].
We have previously studied the expression and function of
XIAP and survivin in human hepatocellular carcinomas (HCCs)
[15,16] and demonstrated that downregulation of XIAP or
survivin by siRNA sensitized TRAIL-induced apoptosis in
HCC cells [24]. Bcl-xL, an anti-apoptotic member of the Bcl-2
family, is located mainly on the outer membrane of mitochon-
dria and inhibits a common pathway of apoptosis by preventing
the release of cytochrome c into the cytosol [43,44]. Bcl-xL was
also over-expressed in HCC tissues and downregulation of Bcl-
xL stimulated apoptosis in HCC cells in response to cellular
stress [45].A) Adv-Casp8 at MOI of 10 or (B) MOI of 50, mitochondrial (M) and cytosolic
cytochrome c. COX IVand α-Tubulin were used as controls for detection of the
densitometry. Their ratios to either COX IVor α-Tubulin are expressed under the
n columns, MOI of 50; closed columns).
Fig. 6 (continued).
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sensitization of TRAIL by caspase-8 gene transfer. Immunoblot
analysis revealed that at MOI of 10, Adv-Casp8 had a little
effect on the level of c-FLIP, XIAP, survivin, or Bcl-xL,
although it augmented TRAIL-induced apoptosis. These results
suggested that a small amount of procaspase-8 over-expression
cannot inhibit function of anti-apoptotic proteins. However,
slight over-expression did have a significant affect on
sensitization to TRAIL, presumably because introduction of
the transgene resulted in an increase in the ratio of procaspase-
8 to c-FLIP. These results also indicate that TRAIL-induced
signaling was converted from acting on the proliferation
pathway to acting on the apoptosis pathway and subsequently,
TRAIL-induced apoptosis was augmented.
Moreover, we demonstrated that at MOI of 20, Adv-Casp8
augmented cell death induced by chemotherapeutic agents in all
HCC cells examined. There are several reports that describe the
mechanism of chemotherapeutic agent-induced cell death in
HCC cells. Chemotherapeutic drug-induced apoptosis is medi-
ated by the CD95 (Apo-1/Fas) receptor/ligand system in HCC
cells and involves activation of wild-type p53 [46]. Moreover,
mediation can act via Fas-dependent or Fas-independent path-
ways [47]. Analysis of the TRAIL DISC after treatment with
chemotherapeutic drugs (for example, 5-FU) revealed upregula-
tion of TRAIL-R2; enhanced caspase-8 recruitment to and
activation at the DISC; and downregulation of c-FLIP in HCC
cells with either wild-type or null p53 status [48]. Our current
study indicates that sensitization to chemotherapeutic drugs by
Adv-Casp8 did not depend on p53 status, suggesting the clinical
utility of the approach in HCC cells independent of p53 status.
We have recently demonstrated that chemotherapeutic agents
sensitize HCC cells to TRAIL-induced apoptosis [29]. These
reports indicated that chemotherapeutic agent-induced cell deathis closely related to death receptor signaling. Together with the
current study, the results suggested that exogenous over-
expression of caspase-8 may be essentially critical for induction
of HCC cell death by chemotherapeutic drugs.
The mitochondrial pathway is an important alternative path-
way for apoptosis via death receptor signaling. In the mitochon-
drial pathway, death signals lead to changes in permeability of the
mitochondrial membrane and a subsequent release of pro-apop-
totic factors, such as cytochrome c [49] and a second mitochon-
drial-derived activator of caspase (Smac)/ the direct IAP binding
protein with low pI (DIABLO) [50,51]. Cytosolic cytochrome c
binds to Apaf-1 and the resulting complex activates procaspase-9,
which in turn activate several downstream caspases, including
caspase-3 [52]. Smac/DIABLO also functions to promote caspase
activation by inhibiting IAP family proteins. In this study,
activation of caspase-8 by Adv-Casp8 atMOI of 50 promoted the
release of cytochrome c and Smac/DIABLO from the mitochon-
dria into the cytosol. Also, Adv-Casp8 resulted in a decrease in the
expression of procaspase-3. Thus, we can conclude that Adv-
Casp8 processed procaspase-3 not only directly but also by
release of cytochrome c, leading activation of caspase-9. In
addition, downregulation of c-FLIP, XIAP and survivin by Adv-
Casp8 may be caused by not only inhibition of NF-κB but also by
Smac/DIABLO. That is, mitochondrial activation by Adv-Casp8
appears to play a role in elimination of factors that normally
confer resistance to TRAIL in HCC cells and thus helps to
augment TRAIL- or chemotherapeutic agent-induced cell death.
In summary, adenovirus vector-mediated gene transfer of
caspase-8 induced apoptosis via downregulation anti-apoptotic
proteins such as c-FLIP, XIAP, survivin, and Bcl-xL, critical
factors for the normal resistance of HCC cells to several cancer
therapies. Moreover, Adv-Casp-8 augmented TRAIL- and
chemotherapeutic agent-induced cell death. Finally, Adv-Casp8
852 Y. Yamaguchi et al. / Biochimica et Biophysica Acta 1763 (2006) 844–853activated themitochondria death pathway, releasing cytochrome c
and Smac/DIABLO. We conclude that the combination of Adv-
Casp8 treatment with TRAIL or chemotherapeutic agents may
provide a useful strategy for treatment of HCC.
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